About Mimi-Q

Mimi-Q develops a virtual clinical trial platform that utilizes patient modeling and adaptive in vitro testing to predict drug behavior and clinical outcomes, significantly reducing development costs by over 80%. This technology addresses the limitations of traditional drug testing methods, which do not accurately reflect the dynamic pharmacokinetics experienced in human populations.

```xml <problem> Traditional drug testing methods often fail to accurately replicate the complex pharmacokinetics observed in diverse human populations, leading to inaccurate predictions of drug behavior and clinical outcomes. This can result in costly late-stage failures and delays in bringing crucial medications to market. </problem> <solution> Mimi-Q offers a virtual clinical trial platform that leverages patient modeling and adaptive in vitro testing to predict drug behavior and clinical outcomes. The platform uses proprietary software to simulate drug behavior in diverse patient populations, incorporating various patient characteristics. Paired with a patented wet lab disease response model that generates data on drug response, Mimi-Q's virtual clinical trial simulator bundles data from diverse sources to predict results for various clinical scenarios. This approach aims to streamline the drug development process, reduce development costs, and accelerate access to medications. </solution> <features> - Virtual Patient Generator: Software that simulates drug behavior in human populations, accounting for diverse patient characteristics. - Wet Lab Disease Response Model: Patented technology that generates data on drug response after administration. - Virtual Clinical Trial Simulator: Platform that integrates data from diverse sources to predict clinical trial outcomes for various scenarios. </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions seeking to accelerate drug development, reduce costs, and improve the accuracy of clinical trial predictions. </target_audience> ```

What does Mimi-Q do?

Where is Mimi-Q located?

Mimi-Q is based in Zürich, Switzerland.

When was Mimi-Q founded?

Mimi-Q was founded in 2023.

Location

Zürich, Switzerland

Founded

2023

Employees

4 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Mimi-Q

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

mimi-q.com 200+

Founded 2023 – Zürich, Switzerland

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Traditional drug testing methods often fail to accurately replicate the complex pharmacokinetics observed in diverse human populations, leading to inaccurate predictions of drug behavior and clinical outcomes. This can result in costly late-stage failures and delays in bringing crucial medications to market.

Solution

Mimi-Q offers a virtual clinical trial platform that leverages patient modeling and adaptive in vitro testing to predict drug behavior and clinical outcomes. The platform uses proprietary software to simulate drug behavior in diverse patient populations, incorporating various patient characteristics. Paired with a patented wet lab disease response model that generates data on drug response, Mimi-Q's virtual clinical trial simulator bundles data from diverse sources to predict results for various clinical scenarios. This approach aims to streamline the drug development process, reduce development costs, and accelerate access to medications.

Features

Virtual Patient Generator: Software that simulates drug behavior in human populations, accounting for diverse patient characteristics.

Wet Lab Disease Response Model: Patented technology that generates data on drug response after administration.

Virtual Clinical Trial Simulator: Platform that integrates data from diverse sources to predict clinical trial outcomes for various scenarios.

Target Audience

The primary target audience includes pharmaceutical companies and research institutions seeking to accelerate drug development, reduce costs, and improve the accuracy of clinical trial predictions.